Similarly, the poor prognostic implications of a KRAS mutation is more a reflection of the underlying cancer types (5 of 10 being pancreas cancer) as is potentially, the better outcomes associated with prior platinum therapy. Here, KRAS is linked to pancreatic neoplasm.